S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
New CBOE “special perk” helps traders target income every weekend (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Recent Reports Are A Wake-Up Call For Investors (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
Recent Reports Are A Wake-Up Call For Investors (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
New CBOE “special perk” helps traders target income every weekend (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Recent Reports Are A Wake-Up Call For Investors (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
Recent Reports Are A Wake-Up Call For Investors (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
New CBOE “special perk” helps traders target income every weekend (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Recent Reports Are A Wake-Up Call For Investors (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
Recent Reports Are A Wake-Up Call For Investors (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
New CBOE “special perk” helps traders target income every weekend (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Recent Reports Are A Wake-Up Call For Investors (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
Recent Reports Are A Wake-Up Call For Investors (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary

Gracell Biotechnologies Stock Price, News & Analysis (NASDAQ:GRCL)

$5.13
+0.15 (+3.01%)
(As of 12/7/2023 ET)
Compare
Today's Range
$4.90
$5.18
50-Day Range
$2.43
$5.40
52-Week Range
$1.40
$6.99
Volume
324,944 shs
Average Volume
351,803 shs
Market Capitalization
$372.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.67

Gracell Biotechnologies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
166.4% Upside
$13.67 Price Target
Short Interest
Healthy
1.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of Gracell Biotechnologies in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.92) to ($0.97) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

550th out of 960 stocks

Pharmaceutical Preparations Industry

205th out of 381 stocks


GRCL stock logo

About Gracell Biotechnologies Stock (NASDAQ:GRCL)

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China.

GRCL Stock Price History

GRCL Stock News Headlines

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Q3 2023 Gracell Biotechnologies Inc Earnings Call
A Preview Of Gracell Biotechnologies's Earnings
The Latest Analyst Ratings for Gracell Biotechnologies
See More Headlines
Receive GRCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gracell Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/11/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRCL
Fax
N/A
Employees
314
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.67
High Stock Price Target
$20.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+166.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-88,080,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$60,000.00
Book Value
$2.95 per share

Miscellaneous

Free Float
52,328,000
Market Cap
$372.84 million
Optionable
Not Optionable
Beta
-0.77
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report














GRCL Stock Analysis - Frequently Asked Questions

Should I buy or sell Gracell Biotechnologies stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gracell Biotechnologies in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GRCL shares.
View GRCL analyst ratings
or view top-rated stocks.

What is Gracell Biotechnologies' stock price target for 2024?

6 Wall Street research analysts have issued 1 year price targets for Gracell Biotechnologies' stock. Their GRCL share price targets range from $7.00 to $20.00. On average, they predict the company's stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 166.4% from the stock's current price.
View analysts price targets for GRCL
or view top-rated stocks among Wall Street analysts.

How have GRCL shares performed in 2023?

Gracell Biotechnologies' stock was trading at $2.30 on January 1st, 2023. Since then, GRCL stock has increased by 123.0% and is now trading at $5.13.
View the best growth stocks for 2023 here
.

When is Gracell Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 11th 2024.
View our GRCL earnings forecast
.

How were Gracell Biotechnologies' earnings last quarter?

Gracell Biotechnologies Inc. (NASDAQ:GRCL) announced its quarterly earnings data on Monday, November, 13th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.16.

When did Gracell Biotechnologies IPO?

(GRCL) raised $150 million in an IPO on Friday, January 8th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Citigroup, Jefferies, Piper Sandler and Wells Fargo Securities acted as the underwriters for the IPO.

Who are Gracell Biotechnologies' major shareholders?

Gracell Biotechnologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (14.97%), Hudson Bay Capital Management LP (2.75%), Pivotal bioVenture Partners Investment Advisor LLC (1.89%), Adage Capital Partners GP L.L.C. (1.17%), Schonfeld Strategic Advisors LLC (1.04%) and Barclays PLC (0.43%).

How do I buy shares of Gracell Biotechnologies?

Shares of GRCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GRCL) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -